RELATED CONTENT
July 11, 2023 — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative ...
July 11, 2023 
Here are several updates in medical imaging contrast media agents. Two of the biggest news items were related to safety ...
July 28, 2017 
Results from Lantheus Medical Imaging Inc.’s first Phase 3 study of flurpiridaz F 18 for myocardial perfusion imaging (MPI) were presented at the International Conference on Nuclear Cardiology and Cardiac CT (ICNC12) in Madrid, Spain. The oral presentation was made by Jamshid Maddahi, M.D., professor of medicine (cardiology) and molecular & medical pharmacology (nuclear medicine), David Geffen School of Medicine at UCLA, in the “Important Clinical Trials and Registries in Nuclear Cardiology” session of ICNC12.
May 04, 2015 
February 4, 2015 — Lantheus Medical Imaging Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ...
February 04, 2015 
Lantheus Medical Imaging Inc. announced an agreement with the Institute for Radioelements (IRE) for the future supply of Xenon Xe 133 Gas (Xenon 133).
January 30, 2015 Lantheus Medical Imaging Inc. and Shine Medical Technologies Inc. announced that the companies have entered into a strategic agreement for the future supply of molybdenum-99 (Mo-99). The supply agreement marks Lantheus’ first with a prospective United States supplier of Mo-99.
November 07, 2014 October 25, 2012 — Lantheus Medical Imaging Inc. announced it has extended its contract with Nordion to supply molybdenum-99 (Mo-99) for use in its TechneLite (Technetium Tc-99m) generators.
October 25, 2012 
February 29, 2012 — Lantheus Medical Imaging Inc. announced a strategic distribution arrangement for its Definity cardiac ultrasound contrast agent in the People’s Republic of China, including Hong Kong S.A.R. and Macau S.A.R.
February 29, 2012